Literature DB >> 3044776

Reproductive endocrine disorders in women with primary generalized epilepsy.

L Bilo1, R Meo, C Nappi, L Annunziato, S Striano, A M Colao, B Merola, G A Buscaino.   

Abstract

It is known that women suffering from temporal lobe epilepsy may frequently present reproductive endocrine disorders (REDs). We hypothesized that a high occurrence of REDs could be found also in primary generalized epilepsy (PGE), and therefore investigated the hormonal and ovarian echographic profiles in 20 PGE female patients of reproductive age. Fourteen reported normal menstrual cycles, while 6 complained of longstanding menstrual irregularities. All but three patients were receiving antiepileptic drug (AED) therapy. In all subjects, the basal levels of gonadotropins, prolactin, and gonadal steroids were assayed. The response of luteinizing hormone (LH) to gonadotropin-releasing hormone was also investigated and ovarian ultrasonographic findings were evaluated. In five of six patients with menstrual problems (25% of the group), a well-defined RED was diagnosed (polycystic ovarian disease in three cases and hypothalamic ovarian failure in two). The 14 patients with normal menstrual cycles showed an elevation of mean basal follicle-stimulating hormone and prolactin, and a blunting of mean LH response. Our results suggest that a high occurrence of REDs may be found also in PGE. We hypothesize that a neurotransmitter dysfunction might be the common pathogenetic mechanism resulting in both REDs and PGE. The hormonal alterations observed in the patients with normal menstrual cycles seem to support our hypothesis. Previous data seem to rule out a possible AED effect accounting for the hormonal findings observed in our series. However, further studies are needed to confirm our preliminary results.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3044776     DOI: 10.1111/j.1528-1157.1988.tb03770.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  17 in total

1.  Women with epilepsy: can the treatment be worse than the disease?

Authors:  Andres M Kanner
Journal:  Epilepsy Curr       Date:  2005 Jan-Feb       Impact factor: 7.500

2.  Women and epilepsy.

Authors:  Sunila E O'Connor; Mary L Zupanc
Journal:  J Pediatr Pharmacol Ther       Date:  2009-10

3.  Menstrual cycle and ovary alterations in women with epilepsy on antiepileptic therapy.

Authors:  G Murialdo; C A Galimberti; F Magri; P Sampaolo; F Copello; M V Gianelli; E Gazzerro; A Rollero; C Deagatone; R Manni; E Ferrari; A Polleri; A Tartara
Journal:  J Endocrinol Invest       Date:  1997-10       Impact factor: 4.256

Review 4.  Management of epilepsy in women of childbearing age: practical recommendations.

Authors:  Barbara Tettenborn
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 5.  Effect of antiepileptic drugs on reproductive endocrine function in individuals with epilepsy.

Authors:  Jouko I T Isojärvi; Erik Taubøll; Andrew G Herzog
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 6.  Treatment of epilepsy in women of reproductive age: pharmacokinetic considerations.

Authors:  James W McAuley; Gail D Anderson
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 7.  Menstrual cycle dysfunction associated with neurologic and psychiatric disorders: their treatment in adolescents.

Authors:  Hadine Joffe; Frances J Hayes
Journal:  Ann N Y Acad Sci       Date:  2008       Impact factor: 5.691

Review 8.  Pregnancy, epilepsy, and anticonvulsants.

Authors:  Bernhard J Steinhoff
Journal:  Dialogues Clin Neurosci       Date:  2008       Impact factor: 5.986

Review 9.  Hormonal aspects of epilepsy.

Authors:  Page B Pennell
Journal:  Neurol Clin       Date:  2009-11       Impact factor: 3.806

Review 10.  Sex Differences in the Epilepsies and Associated Comorbidities: Implications for Use and Development of Pharmacotherapies.

Authors:  Catherine A Christian; Doodipala Samba Reddy; Jamie Maguire; Patrick A Forcelli
Journal:  Pharmacol Rev       Date:  2020-10       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.